MassMutual Private Wealth & Trust FSB lessened its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 5.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,522 shares of the company’s stock after selling 2,006 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Zoetis were worth $6,113,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in the business. UMB Bank n.a. raised its holdings in shares of Zoetis by 0.9% in the 4th quarter. UMB Bank n.a. now owns 76,807 shares of the company’s stock worth $12,514,000 after buying an additional 661 shares in the last quarter. Trueblood Wealth Management LLC grew its position in Zoetis by 13.6% in the fourth quarter. Trueblood Wealth Management LLC now owns 4,689 shares of the company’s stock valued at $764,000 after acquiring an additional 562 shares during the period. Seilern Investment Management Ltd acquired a new position in Zoetis during the fourth quarter worth $9,552,000. Diversify Wealth Management LLC lifted its holdings in shares of Zoetis by 72.8% during the fourth quarter. Diversify Wealth Management LLC now owns 25,224 shares of the company’s stock valued at $4,120,000 after acquiring an additional 10,630 shares during the period. Finally, LVW Advisors LLC boosted its stake in shares of Zoetis by 59.4% in the 4th quarter. LVW Advisors LLC now owns 2,343 shares of the company’s stock valued at $382,000 after purchasing an additional 873 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.
Zoetis Price Performance
Zoetis stock opened at $166.01 on Monday. The business’s 50-day simple moving average is $170.93 and its 200 day simple moving average is $179.98. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The stock has a market cap of $74.90 billion, a price-to-earnings ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $200.53.
Zoetis Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 32.52%.
Analysts Set New Price Targets
ZTS has been the subject of several analyst reports. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. Leerink Partners started coverage on Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. JPMorgan Chase & Co. raised their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. UBS Group began coverage on Zoetis in a report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Finally, Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus target price of $211.89.
Check Out Our Latest Stock Analysis on Zoetis
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- What Are Some of the Best Large-Cap Stocks to Buy?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How to Invest in Insurance Companies: A GuideĀ
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
- Pros And Cons Of Monthly Dividend Stocks
- There May Still Be Time to Get in on These 3 Trending Biotechs
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.